Navigation Links
New Afatinib (BIBW 2992) Data in Non-Small Cell Lung Cancer Patients Presented at the 2010 ESMO Congress
Date:10/11/2010

RIDGEFIELD, Conn., Oct. 11 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.  In the phase IIb/III LUX-Lung 1 study, afatinib tripled the secondary endpoint of progression free survival (PFS) but did not extend the primary endpoint of overall survival (OS) in late-stage patients with non-small cell lung cancer (NSCLC).(1)      

Afatinib is an investigational orally administered irreversible inhibitor of both the epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2) tyrosine kinases.  Afatinib is under development in several solid tumors including NSCLC, breast and head and neck cancer.

The LUX-Lung 1 trial compared afatinib to placebo in over 580 patients with advanced NSCLC who had received chemotherapy and a prior EGFR tyrosine kinase inhibitor (EGFR TKI; gefitinib or erlotinib);(1) results show:

  • Afatinib did not improve OS compared to placebo – 10.78 months vs. 11.96 months, respectively (HR = 1.08, 95% CI 0.86 to 1.35)(1)
  • As a secondary endpoint, afatinib extended PFS three-fold compared to placebo (3.3 months vs. 1.1 months) (HR = 0.38, 95% CI 0.31 to 0.48, p<0.0001).  The improvement in PFS was apparent across all patient subgroups and has been confirmed by independent review(1)
  • At 8 weeks, there was a significantly higher disease control rate (stable disease and tumor shrinkage) in those patients who took afatinib (58%) vs. those taking placebo (19%), which was also independently verified (p<0.0001)(1)
  • Improvement of the lung cancer-related symptoms of cough, dyspnea and pain was observed in the afatinib arm vs. placebo.  In addition, the time to deterioration of cough, individual dyspnea items an
    '/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
5. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
8. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Research and Markets has announced the ... of Pharmaceutical Equipment Market in China, 2014-2018" report ... Trend Forecast of Pharmaceutical Equipment Market in ... pharmaceutical equipment industry in the aspects of ... business performance of domestic major enterprises, as well as ...
(Date:8/29/2014)...   Vittamed Corporation , a neurodiagnostics medical device company ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, ... " Teo Forcht Dagi is an ... and venture capital," said Remis Bistras , President and ... clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... -- Diseases largely eradicated in the United ... was declared eliminated in 2000, yet the CDC reports ... highest incidence in 20 years. In July, ... a problem of "epidemic proportions." ... these preventable diseases—in part because some parents (more than ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... AUSTIN, Texas, March 4, 2011 Vermillion, Inc. (Nasdaq: ... Gail Page, Vermillion,s Chief Executive Officer, will be presenting at ... Ritz Carlton, Laguna Niguel in Dana Point, CA. ... 1:00 p.m. Pacific. The presentation will be web cast and ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... extracellular matrix , today announced it plans to ... March 11, 2011 before the open of the financial ... call with the investment community at 8:00 a.m. PT ...
Cached Medicine Technology:Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA 2Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA 3Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11 2
(Date:8/29/2014)... August 29, 2014 According to this latest ... detection tool at the moment, as it is amazingly effective. ... hardware detection tool in the industry. , Driver Robot ... hardware driver. The new program is highly effective in finding ... work perfectly. , Daily Gossip writes in its Driver ...
(Date:8/29/2014)... Daily Gossip reveals in its Stop Sciatica in 8 ... naturally curing this disease. , The program promises to ... in only one week. This is described as a unique ... sacrifices. , Moreover, with this new method patients might ... in just 8 minutes. , Interested customers can check ...
(Date:8/29/2014)... Famous review website Top10BestSEOHosting.com compares many popular hosting ... most recommended suppliers for webmasters for webmasters who want ... cloud hosting) at affordable prices. , GoDaddy offers ... shared hosting plans depends on the length of a ... for its flexible hosting packages, decent uptime record and ...
(Date:8/29/2014)... The new review that can be read ... holistic system that will permanently eliminate the symptoms of this ... can achieve a cure in as fast as 30 to ... only about one week. , The Tinnitus Miracle review ... as mild hearing loss, pain in the ear and dizziness. ...
(Date:8/29/2014)... August 29, 2014 Cosmetic Town has ... and authenticity of its doctors. Cosmetic Town utilizes ... most renowned doctors in their field are chosen to ... patients have a direct link to potentially hundreds of ... will be able to communicate through the site’s community ...
Breaking Medicine News(10 mins):Health News:Driver Robot Review Exposes Popular Hardware Detection Tool 2Health News:Stop Sciatica in 8 Minutes Review Exposes Steven Guo's Complete Sciatica Cure 2Health News:Tinnitus Miracle Review Reveals How to Gain Tinnitus Relief in 7 Days 2Health News:Cosmetic Town Now Advocates for the Rights of Cosmetic Patients Using Novel Approach 2
... at Washington University School of Medicine in St. Louis ... the immune cells long thought to be responsible for ... examine the immune cells from isolated insulin-making structures in ... caught the immune cells, known as dendritic cells, "red-handed": ...
... Retired Air Force,Colonel Mike Turner, a Democratic candidate for ... Care Countdown" inspired by MSNBC host,Keith Olbermann. Today is ... and a key architect of Hillary Clinton,s,notorious 1993 health ... to tell 10th District voters what, if any, plan ...
... Grant of Emergency Aid through Dubai Cares, DUBAI, ... bin Rashid Al Maktoum, Vice President and Prime Minister ... provision of 200,temporary structures to be used as schools ... has accepted Dubai,s donation. The,official death toll currently stands ...
... SANTA MONICA, Calif., May 9 Dakim, Inc., ... iconic figure in,health and fitness, has signed on ... the company,s [m]Power Cognitive Fitness System, joining the,company,s ... Dakim,s [m]Power is a touch screen-based brain workout ...
... Roche announced today that Sarah,Vidal, M.P.H., product ... a 2008 Rising Star by the Healthcare Businesswomen,s,Association ... May 8,2008 in New York City., "Sarah ... of,confidence, energy, experience, contagious enthusiasm and respect for,others ...
... visible presence for world,s largest surgical,organization, WASHINGTON, May ... ground for a new home for its Washington, D.C.,office ... Hill. The,10-story, class A office building, located at 20 ... of 2010. ACS headquarters will remain in its,current location ...
Cached Medicine News:Health News:Suspected cause of type 1 diabetes caught 'red-handed' for the first time 2Health News:Suspected cause of type 1 diabetes caught 'red-handed' for the first time 3Health News:Mike Turner, Virginia Congressional Candidate, Starts Healthcare Countdown 2Health News:Dubai Provides Aid for Cyclone Nargis Victims In Myanmar 2Health News:Physical Fitness 'Godfather' Jack LaLanne Turns to Brain Fitness, Becoming Ambassador for Dakim's [m]Power System 2Health News:Roche's Vidal Honored as 2008 HBA Rising Star 2Health News:American College of Surgeons Breaks Ground on New Office Building on Capitol Hill 2
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
Medicine Products: